Metabolon and Cardiff University's Division of Psychological Medicine and Clinical Neuroscience Join Forces for Advancing Multiple Sclerosis Research
Wednesday, March 13, 2024
Metabolon, Inc., a leading provider of metabolomics solutions driving advancements in various fields such as life science research, diagnostics, therapeutic development, and precision medicine, has announced a strategic partnership with the Division of Psychological Medicine and Clinical Neuroscience (DPMCN) at Cardiff University, a renowned institution known for its biomedical research. This collaboration aims to uncover novel biomarkers that could accelerate progress in understanding and treating multiple sclerosis (MS).
MS is a neuroinflammatory condition affecting the central nervous system, presenting a spectrum of physical and neuropsychological challenges. With over 2.8 million individuals worldwide living with MS, there remains uncertainty about its precise causes, though it's widely acknowledged that both genetic predisposition and environmental factors contribute. Metabolomics, which explores the intricate interplay of genetic and environmental influences, is thus crucial for unraveling the disease's complexities.
DPMCN has long been engaged in tracking MS patients and pioneering advanced tools for clinicians and researchers. The collaboration will concentrate on analyzing plasma and cerebrospinal fluid (CSF) samples from MS patients, offering a longitudinal perspective by examining repeated samples from the same individuals. This approach allows for a nuanced understanding of disease progression at the individual level, essential given MS's inherent heterogeneity.
Moreover, the study includes patients with primary progressive MS, a rare form characterized by continuous disease progression without remission periods, and lacking approved therapies. Some patients have also undergone genotyping, enabling the integration of multiple omics data to gain a comprehensive understanding of MS's molecular mechanisms, potentially paving the way for new therapeutic strategies.
Dr. Emma Tallantyre, a Clinical Reader at Cardiff University, remarked, "Predictive biomarkers are crucial for tailoring personalized care for MS patients. This collaboration will provide detailed metabolomic profiles from a large, longitudinally followed cohort, complementing existing multidimensional data. It presents an exciting opportunity to refine predictive models, aiming for more accurate outcome predictions for MS patients."
Dr. Karl Bradshaw, Chief Business Officer at Metabolon, added, "MS currently lacks a cure, with only disease-modifying therapies available to slow its progression. By harnessing Cardiff's extensive research capabilities and our decades of expertise in generating top-quality and precise metabolomics data, we aspire to redefine our understanding of MS, potentially making a profound impact on the lives of those affected by this debilitating disease."
Source: metabolon.com
